Top

American Journal of Clinical Dermatology

Published in:

01-02-2002 | Review Article

The Role of Fluoroquinolones in Skin and Skin Structure Infections

Author: Dr Joseph M. Blondeau

Published in: American Journal of Clinical Dermatology | Issue 1/2002

Abstract

Skin and skin structure infections encompass a broad range of clinical presentations and disease severity. Antimicrobial therapy is clearly beneficial for both recovery from these infections as well as preventing disease progression. Fluoroquinolones are potent broad spectrum antimicrobial agents with the older agents characterized as having broad spectrum anti-Gram-negative activity, borderline activity against clinically important Gram-positive pathogens and little or no anti-anaerobic bacteria activity. In contrast, the new quinolones are characterized by having enhanced activity against Gram-positive pathogens, anti-anaerobic activity and they remain highly active against aerobic-Gram-negative bacilli. Several fluoroquinolones have been evaluated for the treatment of uncomplicated skin and soft tissue infection, difficult skin and soft tissue infection and serious skin and skin structure infections. Clinical cure rates were found to be equivalent to comparators suggesting a role for the fluoroquinolone in treating these infections. It may be necessary to use some fluoroquinolones in combination with anti-anaerobic agents for those infections with mixed aerobic and anaerobic pathogens. Some additional clinical trials are necessary to identify the full potential of newer fluoroquinolones for skin and skin structure infections. At present, quinolones are, in general, equivalent to β-lactam agents in the treatment of skin and soft tissue infection.

Sacks J.J., Kresnow M., Houston B. Dogbites: how big a problem? Injury Prev 1996; 2: 52–4CrossRef

Goldstein E.J.C. Bite wounds and infection. Clin Infect Dis 1992; 14: 633–40PubMedCrossRef

Blondeau J.M. Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. Expert Opin Investig Drugs 2001; 10 (2): 213–37PubMedCrossRef

Goldstein E.J.C., Citron D.M., Merriam C.V., et al. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections. Antimicrob Agents Chemother 1999; 43 (6): 1475–9PubMed

Ednie L.M., Jacobs M.R., Appelbaum P.C. Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother 1998; 42: 2459–62PubMed

Schaumann R., Ackermann G., Pless B., et al. In vitro activities of gatifloxacin, two other quinolones and five nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 1999; 43: 2783–6PubMed

Appelbaum P.C. Quinolone activity against anaerobes. Drugs 1999; 58 Suppl. 2: 60–4PubMedCrossRef

Blondeau J.M., Zhao X., Drlica K., et al. Comparison of moxifloxacin, levofloxacin and gatifloxacin by the mutation prevention concentration (MPC) using clinical isolates of Streptococcus pneumoniae (SP) [abstract no. E2325]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

Blondeau J.M., Laskowski R., Bjarnason J., et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 gram-negative and gram-positive organisms. Int J Antimicrob Agents 2000; 14: 45–50PubMedCrossRef

10.

Blondeau J.M., Borsos S. In vitro susceptibility of 4768 bacterial isolates to gemifloxacin: an advanced fluoroquinolone [abstract no. E2309]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17–20; Toronto

11.

McCloskey L., Moore T., Niconovich N., et al. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J Antimicrob Chemother 2000; 45: 13–21PubMedCrossRef

12.

Blondeau J.M., Hansen G., Zhao X., et al. Comparison of ciprofloxacin (C) and levofloxacin (L) by the mutation prevention concentration (MPC) against clinical isolates of Pseudomonas aeruginosa (PA). Chest 2000; 118 Suppl. 4: S132

13.

Blondeau J.M., Zhao X., Hansen G., et al. Mutant prevention concentration (MPC) for fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 433–8PubMedCrossRef

14.

Goldstein E.J.C. Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens. J Antimicrob Chemother 2000; 45 Suppl. 1: 55–65PubMedCrossRef

15.

Blondeau J.M., Church D., Yaschuk Y., et al. In vitro activity of several antimicrobial agents against 1003 isolates of Streptococcus pyogenes collected from Western Canada. Int J Antimicrob Agents 1999; 12: 67–70PubMedCrossRef

16.

Barry A.L., Fuchs P.C., Brown S.D. Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA. J Antimicrob Chemother 1997; 40: 139–40PubMedCrossRef

17.

Doern G.V., Jones R.N., Pfaller M.A., et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). The Sentry Study Group (North America). Diagn Microbiol Infect Dis 1999; 34: 65–72PubMedCrossRef

18.

Goldstein E.J.C. Bite wounds: current treatment options. Curr Treat Options Infect Dis 2000; 2: 173–80

19.

Nicodemo A.C., Robledo J.A., Jasovich A., et al. A multicenter, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract 1998 Mar; 52 (2): 69–74PubMed

20.

Nichols.R.E, Smith J.W., Gentry L.O., et al. Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J 1997 Dec; 90: 1193–200PubMedCrossRef

21.

Taarshis G., Miskin B.M., Jones T.M., et al. Oral gatifloxin (GAT), 400 mg QD, vs. oral levofovacin (LEV), 500 mg QD, in the treatment of uncomplicated skin and soft tissue infections (SSTI) [abstract no. 1075]. 39th Interscience Conference on Antimicrobial Agents and Chemotherpy; 1999 Sep 26–29; San Francisco, CA: 716

22.

Leal del Rosal P., Martinez R., Fabian G., et al. Efficacy and safety of moxifloxacin vs. cephalexin in the treatment of mild to moderate uncomplicated skin and soft tissue infections (uSSSI) [abstract no. P493]. 21st International Congress of Chemotherapy; 1999 Jul 4–7; Birmingham, UK

23.

Parish L.C., Heyd A., Haverstock D., et al. Efficacy and safety of moxifloxacin vs. cephalexin in the treatment of mild to moderate acute uncomplicated skin and skin structure infections [abstract no. P441]. 21st International Congress of Chemotherapy; 1999 Jul 4–7; Birmingham, UK

24.

Stoner B.P., Douglas J.M., Martin D.H., et al. Single-dose gatifloxacin (400 mg or 600 mg) vs. single-dose ofloxzacin (400 mg) in the treatment of uncomplicated gonococcal infections [abstract no. 1744]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, CA: 688

25.

Gentry L.O., Ramirez-Ronda C.H., Rodriguez-noreiga E., et al. Oral ciprofloxacin vs parenteral cefotaxime in treatment of difficult skin and skin structure infections: a multicenter trial. Arch Intern Med 1989; 149: 2579–83PubMedCrossRef

26.

Fass R.L., Plouffe J.F., Russell J.A. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med 1989; 18 Suppl. D: 2

27.

Gentry L.O., Rodriguez-Gomez G., Celuff B.J., et al. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am J Med 1989; 87 Suppl. 6C: S57–60CrossRef

28.

Berry V., Page R., Satterfield J., et al. Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection. J Antimicrob Chemother 2000; 45 Suppl. S1: 87–93PubMedCrossRef

29.

Parish L.C., Routh H.B., Miskin B., et al. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract 2000; 54 (8): 497–503PubMed

30.

Archibald L., Phillips L., Monnet D., et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997; 24: 211–5PubMedCrossRef

31.

Pfaller M.A., Jones R.N., Doern G.V. Bacterial pathogens isolated from patients with blood stream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada 1997). Antimicrob Agents Chemother 1998; 42 (7): 1762–70PubMed

32.

Karchmer A.W. Fluoroquinolone treatment of skin and skin structure infections. Drugs 1999; 58 Suppl. 2: 82–4PubMedCrossRef

33.

Siefert H., Kohlsdorfer W., Steinke W., et al. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. J Antimicrob Chemother 1999; 43 Suppl. B; 61–7PubMedCrossRef

34.

Perry C.M., Barman-Balfour J.A., Lamb H.M. Gatifloxacin. Drugs 1999; 58 (4): 683–96PubMedCrossRef

35.

Blondeau J.M. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther 1999; 21: 3–40PubMedCrossRef

36.

Ball P., Mandell L., Niki Y., et al. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 1999 Nov; 21 (5): 407–21PubMedCrossRef

Title: The Role of Fluoroquinolones in Skin and Skin Structure Infections
Author: Dr Joseph M. Blondeau
Publication date: 01-02-2002
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 1/2002
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200203010-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Role of Fluoroquinolones in Skin and Skin Structure Infections

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2002

New and Established Topical Corticosteroids in Dermatology

Cutaneous Drug Reaction Case Reports

Fungal Skin Infections in Organ Transplant Recipients

Changing Morbidity of Cutaneous Diseases in Patients with HIV After the Introduction of Highly Active Antiretroviral Therapy Including a Protease Inhibitor

Diagnosis and Treatment of Scabies

Impact of Increasing Antimicrobial Resistance on Wound Management